Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Caligiuri
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Precision Technologies, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Michael Caligiuri is the Principal Investigator on this research project, and holds equity interests in Precision Technologies, LLC and Cytoimmune Therapeutics, LLC, both privately-held companies. The City of Hope Conflict of Interest and Commitment Committee (“COICC”) has determined that Dr. Caligiuri’s interests in Precision Technologies, LLC and Cytoimmune Therapeutics, LLC relate to the grant as the research centers on understanding and optimizing human NK cell development, and developing a bi-specific NKG2D antibody that will bring human NK cells into the tumor bed. Precision Technologies, LLC has a similar business focus and acquires and develops biologic and immunological compounds for use in oncology treatment and therapies with the goal of commercializing them. The intention is to merge Precision’s Technologies, LLC technology into Cytoimmune Therapeutics, LLC’s.
Human natural killer cells: Advancing biology and clinical applications
PROJECT NARRATIVE Natural killer (NK) cells serve as a crucial first line of defense against cancer. Funding of this proposal will advance our understanding of basic immunology on human NK cells as well as advance the development of NK cell-based immunotherapy to treat cancer. The knowledge and therapeutic advances obtained from this study will add a new dimension to the armamentarium against cancer.
Filed on January 28, 2019.
Tell us what you know about Michael Caligiuri's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Michael Caligiuri filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michael Caligiuri | Beckman Research Institute/city of Hope | Conflict of Interest | Cytoimmune Therapeutics, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.